Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: @on2u - only 25% correct...;-)

"100% of the shares subject to the Event Bonus Option will vest, and Executive's interim position will be converted to standing President/CEO, upon the effective date of any one of the following events: (i) the successful closing of a merger or acquisition brought forth primarily due to the efforts of Executive (excluding any merger or acquisition with TPL or any affiliated company) as approved by the Board of Directors; (ii) the listing of the Company on the Amex or NASDAQ stock exchanges as approved by the Board of Directors; (iii) a "sustained substantial increase in shareholder value" (as defined below) directly resulting from an Executive action approved by the Board of Directors; or (iv) approval by the Board of Directors for the partial vesting of the Event Bonus Option. For purposes of this section, a "sustained substantial increase in shareholder value" shall be defined as follows: "an sustained increase in Patriot's Market Capitalization to over $400 million for a period of no less than 90 days. "

As you can see, there are several possibilities, when the 2mio shares will vest - the Market Cap of over $400 million ist just ONE of four possible options and is not necessary for the vesting of the shares.

RG accomplished point 1 (successful closing of an acquisition), didn't pursue point 2 (listing on Amex/Nasdaq, failed in point 3 (increase in shareholder value) - and point 4 is up to the BoD.

If one sees the merger with Crossflo as the fulfilled condition of point 1, RG could be allowed to vest the 2mio shares.

GLTY

Share
New Message
Please login to post a reply